Skip to main content

Healthy Elderly

3
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

ABLi Therapeutics
1 program
1
IkT-148009Phase 11 trial
Active Trials
NCT04350177Completed101Est. Jan 2023
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
1
NX210cPhase 11 trial
Active Trials
NCT05827653Completed29Est. Oct 2023
Pfizer
PfizerNEW YORK, NY
1 program
1
PF-06743649Phase 11 trial
Active Trials
NCT02170012Terminated24Est. Sep 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Human BioSciencesNX210c
ABLi TherapeuticsIkT-148009
PfizerPF-06743649

Clinical Trials (3)

Total enrollment: 154 patients across 3 trials

MAD Study of NX210c

Start: Dec 2022Est. completion: Oct 202329 patients
Phase 1Completed

A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's Patients

Start: Feb 2021Est. completion: Jan 2023101 patients
Phase 1Completed

A Study In Healthy Elderly People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses Of PF-06743649

Start: Jul 2014Est. completion: Sep 201424 patients
Phase 1Terminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.